OriGene Technologies, Inc.
9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

Product datasheet for TR304834

EFEMP2 Human shRNA Plasmid Kit (Locus ID 30008)

Product data:

Product Type:	shRNA Plasmids
Product Name:	EFEMP2 Human shRNA Plasmid Kit (Locus ID 30008)
Locus ID:	30008
Synonyms:	ARCL1B; FBLN4; MBP1; UPH1
Vector:	pRS (TR20003)
E. coli Selection:	Ampicillin
Mammalian Cell Selection:	Puromycin
Format:	Retroviral plasmids
Components:	EFEMP2 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 30008). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
RefSeq:	NM_016938, NR_037718, NM_016938.1, NM_016938.2, NM_016938.3, NM_016938.4, BC010456, BC010456.1, BC018871, BC109225
UniProt ID:	O95967
Summary:	A large number of extracellular matrix proteins have been found to contain variations of the epidermal growth factor (EGF) domain and have been implicated in functions as diverse as blood coagulation, activation of complement and determination of cell fate during development. The protein encoded by this gene contains four EGF2 domains and six calcium-binding EGF2 domains. This gene is necessary for elastic fiber formation and connective tissue development. Defects in this gene are cause of an autosomal recessive cutis laxa syndrome. Alternatively spliced transcript variants have been identified for this gene. [provided by RefSeq, Jan 2011]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.

View online »

Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).